Trial Profile
An Observational study to evaluate the clinical response of Denosumab and Concomitant immunotherapies in patients with advanced Melanoma or Non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2018
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Ipilimumab; Nivolumab; Pembrolizumab
- Indications Malignant melanoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology